In the future, targeted inhibitors against SRSF10 will be found to potentially inhibit M2 macrophage polarization, thereby enhancing the efficacy of anti-PD-1 hepatocellular carcinoma therapy (Cai et al., 2024). Here, PDCD1 is linked to hepatocellular carcinoma.